Catalyst Event

OliX Pharmaceuticals Inc (226950) · Other

From KRX Bio Technology Transfer Index (KBIOTT)

3/24/2026, 12:00:00 AM

OtherSentiment: Positive

Announcement of positive preclinical results for obesity treatment OLX501A showing 84% ALK7 gene suppression in primates and plans to accelerate development expected. High efficacy in primate studies is estimated to result in a price impact of over 5%, expected.

Korean Translation

차세대 비만 치료제 OLX501A의 영장류 전임상 결과 발표 및 84% 유전자 억제 효능 확인, 개발 가속화 계획이 예상됨. 높은 효능에 따른 5% 이상의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline